Search

everythinglearnresearchcommunity

for

Search:↓

3α-AdiolG is a good marker for androgen activity in women with excessive hair growth and decreases with anti-androgen treatment.

ADT-G may be a useful indicator of increased androgen levels in women with acne and can be lowered with certain birth control pills.

Testosterone increases 3α-androstanediol levels, which can be blocked by finasteride.

The study found that urine metabolites M1b or M4 are the best indicators of ATD use in horses, with detection possible up to 77 hours in urine and 28 hours in blood.

A new compound with strong antiandrogenic effects was found, potentially useful for treating conditions like acne and prostate cancer.

Women with more 3α,17β-androstanediol glucuronide compared to sex hormone binding globulin are more likely to have female pattern baldness.

Higher levels of a specific hormone are linked to more chest hair and acne in men.

A 17-year-old female with adrenogenital syndrome produces very high levels of androgens, which prevent complete feminization despite high estrogen doses.

Testosterone affects androgen receptors and lipid storage in cells, while DHEA does not convert to testosterone or affect these receptors in the same way.

The document concludes that a compound with potential for treating prostate cancer and hair loss was successfully made and its detailed structure was confirmed.

Chronic DHEA supplementation slightly increases testosterone in hair but stays within safe limits.

Higher levels of 3α-diol G are linked to more severe female pattern hair loss.

A new compound that could treat various androgen-related conditions was created and analyzed.

Men with androgenetic alopecia do not have elevated DHEA-S levels.

Men with hair loss don't necessarily have higher levels of the hormone DHEA-S, but this hormone tends to decrease with age.

Human liver enzyme DHEA ST helps process minoxidil.

Some synthesized compounds were more effective than Finasteride in reducing prostate cancer cell growth and androgen levels.

New chemical compounds were made that effectively block an enzyme linked to prostate growth.

Men with male pattern baldness don't necessarily have high levels of Dehydroepyandrosterone-sulfate, and there's no link between its levels and the severity of hair loss.

New A-homo-B, 19-dinor steroids showed strong antiandrogenic activity without affecting the enzyme 5α-reductase or androgen receptor binding.

A new compound was made that might help treat diseases related to male hormones.

Higher testosterone and DHEA-S levels may be linked to male pattern baldness.

The compound was successfully made and shows potential for treating prostate cancer.

Researchers developed a reliable way to measure hormones in urine, showing that a baldness treatment doesn't change hormone levels.

DHT inhibition may increase spinal bone growth in ankylosing spondylitis.

The method effectively measures drug impact on DHT levels in prostate treatments.

A new method was developed to make a compound used in finasteride and epristeride with a 69% yield.